Wyeth: Domestic Centrum sales rose 6% to $93.7 mil. in Q2, making it the only consumer brand of seven broken out by Wyeth to post positive U.S. results in the period. Brand revenue may have been helped by launch of Centrum Performance energy nutrition bars, in stores now (1"The Tan Sheet" May 6, 2002, p. 9). Advil sales fell 11.1% to $93.2 mil. in the U.S., while domestic Caltrate sales were off 10.6% at $15.2 mil. Similar to other cough/cold product manufacturers, Wyeth's financials were negatively impacted by a mild U.S., winter, with both Robitussin (down 9.7%) and Dimetapp (off 8.1%) feeling the effects. Consumer healthcare sales dropped 4% in U.S. to $308.4 mil. and were flat worldwide at $493.1 mil., Wyeth says in 2July 23 earnings release...

Wyeth: Domestic Centrum sales rose 6% to $93.7 mil. in Q2, making it the only consumer brand of seven broken out by Wyeth to post positive U.S. results in the period. Brand revenue may have been helped by launch of Centrum Performance energy nutrition bars, in stores now (1"The Tan Sheet" May 6, 2002, p. 9). Advil sales fell 11.1% to $93.2 mil. in the U.S., while domestic Caltrate sales were off 10.6% at $15.2 mil. Similar to other cough/cold product manufacturers, Wyeth's financials were negatively impacted by a mild U.S., winter, with both Robitussin (down 9.7%) and Dimetapp (off 8.1%) feeling the effects. Consumer healthcare sales dropped 4% in U.S. to $308.4 mil. and were flat worldwide at $493.1 mil., Wyeth says in 2July 23 earnings release...

Wyeth: Domestic Centrum sales rose 6% to $93.7 mil. in Q2, making it the only consumer brand of seven broken out by Wyeth to post positive U.S. results in the period. Brand revenue may have been helped by launch of Centrum Performance energy nutrition bars, in stores now (1"The Tan Sheet" May 6, 2002, p. 9). Advil sales fell 11.1% to $93.2 mil. in the U.S., while domestic Caltrate sales were off 10.6% at $15.2 mil. Similar to other cough/cold product manufacturers, Wyeth's financials were negatively impacted by a mild U.S., winter, with both Robitussin (down 9.7%) and Dimetapp (off 8.1%) feeling the effects. Consumer healthcare sales dropped 4% in U.S. to $308.4 mil. and were flat worldwide at $493.1 mil., Wyeth says in 2July 23 earnings release...